Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

6 terminated/withdrawn out of 27 trials

Success Rate

76.0%

-10.6% vs industry average

Late-Stage Pipeline

22%

6 trials in Phase 3/4

Results Transparency

21%

4 of 19 completed trials have results

Key Signals

4 with results6 terminated

Enrollment Performance

Analytics

Phase 2
4(40.0%)
Phase 4
4(40.0%)
Phase 3
2(20.0%)
10Total
Phase 2(4)
Phase 4(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT05527340Phase 2Active Not Recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Role: collaborator

NCT02682641Phase 2Active Not Recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Role: collaborator

NCT03207282Completed

Treatment Resistant Depression in America Latina

Role: lead

NCT02692248Phase 2Completed

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Role: collaborator

NCT04476446Phase 3Completed

An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

Role: lead

NCT03685500Phase 4Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Role: collaborator

NCT03042390Completed

Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice

Role: collaborator

NCT01848132Phase 2Completed

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Role: collaborator

NCT02414984Terminated

Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

Role: lead

NCT00639054Completed

The Molecular Characterization of Multiple Myeloma at Relapse

Role: collaborator

NCT01181921Phase 4Terminated

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00358852Completed

Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia

Role: lead

NCT01867164Phase 3Completed

A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

Role: lead

NCT01262534Completed

A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.

Role: lead

NCT01724359Phase 4Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

Role: lead

NCT01376492Completed

FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain

Role: lead

NCT01402830Completed

Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)

Role: lead

NCT01478204Completed

A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT01309373Completed

An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia

Role: lead

NCT00511966Terminated

Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol

Role: lead